GENinCode's (GENI's) portfolio of clinical genomic tests provides information to enhance standard risk assessment and diagnosis of cardiovascular disease (CVD), which is the highest cause of death globally (over 18 million deaths per annum). FY 2022 financials were in line European/UK revenues of £1.4m, EBITDA loss £5.6m reflecting the scale up of commercial plan, net cash at £9.7m ahead of our £8.4m estimate. The focus is delivering key regulatory and commercial milestones, notably 510k submiss ....
